ESTRO 2024 - Abstract Book

S2350

Clinical - Urology

ESTRO 2024

Univariate analysis results (with focus on therapy parameters) are summarized in Table 1. No statistically significant differences were observed between LH-RH agonists and HDB across all analyzed endpoints. The multivariate analysis identified PSA levels' impact on bRFS (p: 0.003) and Gleason score's influence on bRFS (p<0.001), LC (p<0.001), MFS (p<0.001), and DFS (p<0.001).

Conclusion:

This study reinforces the efficacy of HDB-based ADT when combined with EBRT, suggesting it as a valid treatment option for PCa patients who aim to avoid pharmacological castration.

Keywords: Bicalutamide, Prostate, Equivalence

750

Digital Poster

clinical efficacy of tumor markers in patients with refractory HCC to TACE or RFA who received SABR

Jae-Uk Jeong, Ick Joon Cho, Taek-keun Nam

Chonnam National University Hwasun Hospital, Radiation Oncology, Hwasun, Korea, Republic of

Purpose/Objective:

SABR has been emerging as an effective option for treating localized HCC. This study is performed to evaluate the clinical efficacy of tumor markers in patients who underwent SABR for refractory HCC after TACE or RFA.